Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages 338-347

  Marco, Helena ^a   Mirapeix, Eduard ^b   Arcos, Emma ^c   Comas, Jordi ^c   Ara, Jordi ^d   Gil Vernet, Salvador ^e   Puig, Josep ^f   Vinyas, Odette ^b   Perello, Manel ^e   Oppenheimer, Federico ^b   Poveda, Rafael ^e   Ibernón, Meritxell ^d   Díaz, Montserrat ^a   Ballarin, Jose ^a  

^a FUNDACIÓ PUIGVERT   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Organització Catalana de Transplantaments OCATT   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

Antineutrophil cytoplasmic antibody; Outcomes; Renal transplantation; Vasculitis

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MALE; MEDICAL LITERATURE; NEOPLASM; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; IMMUNOLOGY; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84878668093     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12084     Document Type: Article

References (50)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994: 37: 187.
2. Nachman PH, Hogan SL, Jennette JC. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996: 7: 33.
3. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999: 42: 421.
4. Mukhtyar C, Flossman O, Hellmich B et al. European Vasculitis Study Group (EUVAS). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Task Force. Ann Rheum Dis 2008: 67: 1004.
5. Pagnoux C, Hogan SL, Chin H et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008: 58: 2908.
6. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody associated systemic vasculitis. J Am Soc Nephrol 1998: 9: 1258.
7. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998: 9: 842.
8. Schmitt WH, Opelz G, Van Der Woude FJ. Renal transplantation is safe and successful in Wegener's granulomatosis: data from the Colloborative Transplant Study. J Am Soc Nephrol 2002: 13: 564A.
9. Haubitz M, Kliem V, Koch K et al. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 1997: 63: 1251.
10. Briggs DJ, Jones E. Renal transplantation for uncommon diseases. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999: 14: 570.
11. Deegens JK, Artz MA, Hoitsma AJ, Wetzels JF. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease. Clin Nephrol 2003: 59: 1.
12. Moroni G, Torri A, Gallelli B et al. The long term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007: 7: 2133.
13. Little MA, Hassan B, Jacques S et al. Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant 2009: 24: 3219.
14. Gera M, Griffin MD, Specks U, Leung N, Stegall MD, Fervenza FC. Recurrence of ANCA associated vasculitis following renal transplantation in the modern era of immunosuppression. Kidney Int 2007: 78: 1.
15. Nachman PH, Segelmark M, Westman K et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999: 56: 1544.
16. Booth AD, Wallace S, McEniery CM et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004: 50: 581.
17. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992: 116: 488.
18. Jayne D, Rasmussen N, Andrassy K et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003: 349: 36.
19. De Groot K, Adu D, EUVAS (European Vasculitis Study Group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001: 16: 2018.
20. Kuross S, Davin T, Kjellstrand C. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol 1981: 16: 172.
21. Schmitt WH, Haubitz M, Mistry N, Brunkhorst R, Erbslöh-Möller B, Gross WL. Renal transplantation in Wegener's granulomatosis. Lancet 1993: 342: 860.
22. Stegeman CA, Cohen Tervaert JW, Van Son WJ, Tegzess AM. Necrotizing glomerulonephritis associated with antimyeloperoxidase antibodies in a renal transplant recipient with renal failure of unknown origin. Nephrol Dial Transplant 1994: 9: 839.
23. Grotz W, Wanner C, Rother E, Schollmeyer P. Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 1995: 69: 234.
24. Frasca G, Neri L, Martello M, Sestigiani E, Borgnino LC, Bonomini V. Renal transplantation in patients with microscopic polyarteritis and antimyeloperoxidase antibodies: report of three cases. Nephron 1996: 72: 82.
25. Rostaing L, Modesto A, Oksman F, Cisterne JM, Le Mao G, Durand D. Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997: 29: 96.
26. Nyberg G, Akesson P, Norden G, Wieslander J. Systemic vasculitis in a kidney transplant population. Transplantation 1997: 63: 1273.
27. Elmedhem A, Adu D, Savage C. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003: 18: 1001.
28. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007: 18: 2180.
29. Geetha D, Eirin A, True K et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 2011: 91: 1370.
30. Fan SLS, Lewis KE, Ball E, Dodd S, Raftery MJ, Yaqoob MM. Recurrence of Wegener's granulomatosis 13 years after renal transplantation. Am J Kidney Dis 2001: 38: E32.
31. Reaich D, Cooper N, Main J. Rapid catastrophic onset of Wegener's granulomatosis in a renal transplant. Nephron 1994: 67: 354.
32. Weidanz F, Day CJ, Hewins P, Savage CO, Harper L. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCAassociated vasculitis. Am J Kidney Dis 2007: 50: 36.
33. Lionaki S, Hogan SL, Jennette CE et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 2009: 76: 644.
34. Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998: 13: 1713.
35. Lurati-Ruiz F, Spertini F. Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis. J Rheumatol 2005: 32: 2167.
36. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995: 25: 380.
37. Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002: 17: 2077.
38. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with smallvessel vasculitis. Am J Kidney Dis 2003: 42: 1149.
39. Stone JH, Merkel PA, Spiera R et al., for the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010: 363: 221.
40. Jones RB, Cohen Tervaert JW, Hauser T et al., for the European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010: 363: 211.
41. Rosenstein ED, Ribot S, Ventresca E, Kramer N. Recurrence of Wegener's granulomatosis following renal transplantation. Br J Rheumatol 1994: 33: 869.
42. Sastre A, Baños M, Seco M, Gómez Huertas E. Vasculitis recurrence following renal transplantation: treatment with rituximab. Nefrología 2007: 27: 645.
43. Schewior L, Dragun L, Rudolph B, Schaeffner E. Make the grade for Wegener's granulomatosis after kidney Transplantation. NDT Plus 2009: 2: 199.
44. Shen J, Gill J, Shangguan M, Sampaio MS, Bunnapradist S. Outcomes of renal transplantation in recipients with Wegener′s granulomatosis. Clin Transplant 2011: 25: 380.
45. De Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005: 64: 753.
46. Morgan MD, Turnbull J, Selamet U et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides. A matched-pair cohort study. Arthritis Rheum 2009: 60: 3493.
47. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008: 35: 101.
48. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004: 63: 1307.
49. Heijl C, Harper L, Flossmann O et al., European Vasculitis Study Group (EUVAS). Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011: 70: 1415.
50. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier ML. Malignancy in renal transplantation. J Am Soc Nephrol 2004: 15: 1582.